[Renoprotective Effect of Small Volumes of Hypertonic Saline Solution in Chronic Heart Failure Patients with Marked Fluid Retention: Results of a Case-control Study]
Overview
Affiliations
During intensive therapy of chronic heart failure (CHF) patients with marked fluid retention using high doses of i.v. furosemide the additional effect of agents which might exert osmotic attraction of interstitial fluids has been proposed. They are thought to impede the impairment of renal blood supply and glomerular filtration rate, which may be caused by a combined action of cardiac preload acute reduction, hypotension and neurohormonal activation.We therefore assessed in CHF patients with NYHA class III and BNP values from 900 to 1500 pg/ml, who were treated with i.v. furosemide, the predictors of iatrogenic short term creatinine impairment by means of a case-control observational study from two centers. Patients with CHF had been treated for 6-8 days with intravenous loop diuretics alone or with an additional i.v. administration of other agents (plasma expanders, albumin, mannitol, inotropic support etc.). A rise in serum creatinine ≥ 25% of the basal value was considered as renal impairment.A total of 15 cases and 38 controls were enrolled. At univariate analysis, serum creatinine basal value ≥ 2.2 mg/dl, absence of hypertonic saline solution (HSS) in the therapeutic protocol, hyposodic diet and refractory oligoanuria were associated with an increased risk of worsening renal function precipitated by i.v. diuretic therapy. At multivariate analysis as a predictor of loop diuretic-related renal function impairment, we found a serum creatinine ≥ 2.2 mg/dl at baseline (OR: 63.33, 95% CI: 3.68-1088.73, p=0.0043) and the absence of HSS in the therapeutic regimen (OR: 25.0461, 95% CI: 2.07-302.53, p=0.0113). Moreover, in multivariate analysis ascites had some predictive value of renal deterioration (OR: 13.28, 95% CI: 1.0055-175.41, p=0,0495).
Orozco Burbano J, Saldarriaga Giraldo C, Echeverri Marin D Arch Peru Cardiol Cir Cardiovasc. 2023; 2(4):247-253.
PMID: 37727671 PMC: 10506575. DOI: 10.47487/apcyccv.v2i4.159.
Gatzoflias S, Hao S, Ferreri N Am J Physiol Renal Physiol. 2021; 320(6):F1159-F1164.
PMID: 33969695 PMC: 8285644. DOI: 10.1152/ajprenal.00686.2020.
Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?.
Bielecka-Dabrowa A, Godoy B, Schefold J, Koziolek M, Banach M, von Haehling S Curr Heart Fail Rep. 2018; 15(4):224-238.
PMID: 29987499 DOI: 10.1007/s11897-018-0397-5.
Lafreniere G, Beliveau P, Begin J, Simonyan D, Cote S, Gaudreault V World J Cardiol. 2017; 9(8):685-692.
PMID: 28932357 PMC: 5583541. DOI: 10.4330/wjc.v9.i8.685.
Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure.
Grodin J Curr Heart Fail Rep. 2016; 13(4):181-9.
PMID: 27278221 DOI: 10.1007/s11897-016-0295-7.